Table 5.
Current clinical trials for CRPCa of combination therapies with taxanes
| Clinical Trial | Primary Anticancer Agent | Secondary Anticancer Agent | Phase | Current Status | Estimated Completion Date |
|---|---|---|---|---|---|
| upFrontPSMA (NCT04343885) | Docetaxel | 177Lu-PSMA-617 | II | Recruiting | April 2024 |
| TheraP (NCT03392428) | Post-Docetaxel | 177Lu-PSMA-617 | II | Active, not recruiting | January 2021 |
| NCT02218606 | Cabazitaxel | Abiraterone | II | Active, not recruiting | August 2020 |
| NCT03110588 | Cabazitaxel | Abiraterone and Enzalutamide | I | Recruiting | August 1, 2023 |
| NCT01555242 | Docetaxel | Aneustat | I | Completed (No compiled results) | January 2014 |
| ProCAID (NCT02121639) | Docetaxel | AZD5363 (AKT Inhibitor) | I/II | Active, not recruiting | February 2020 |
| NCT03218826 | Docetaxel | AZD8186 (PI3K Inhibitor) | I | Recruiting | April 1, 2021 |
| NCT01505868 | Cabazitaxel | Carboplatin | I/II | Active, not recruiting | July11, 2030 |
| NCT02522715 | Cabazitaxel | Enzalutamide | I/II | Active, not recruiting | August 31, 2025 |
| PROSTRATEGY (NCT03879122) | Docetaxel/ADT | Nivolummab, Ipilimumab | II/III | Active, not recruiting | December 31, 2023 |
| NCT03834506 | Docetaxel | Pembrolizumab | III | Recruiting | February 28, 2023 |
| NCT02649855 | Docetaxel | PROSTVAC | II | Active, not recruiting | January 1, 2021 |
| NCT01420250 | Cabazitaxel | Radiation (IMRT), Bicalutamide | I | Active, not recruiting | January 1, 2021 |
| NCT02494921 | Docetaxel | Ribociclib (CDK4/6 Inhibitor) | I/II | Active, not recruiting | June 30, 2021 |
Similar to combination therapies with ATTs, many trials are looking to combinations with docetaxel to effectively suppress CRPCa. The intent is to find other therapies that can reduce the amount of taxane necessary for cancer treatment to prevent the toxicities commonly associated with these types of agents.